Psyence Group announces the commencement of online sales and distribution of “GOODMIND™” products

2021-08-18T11:55:44+00:00August 18, 2021|Press Releases, Investor Information, Psychedelic News|

We are excited that as of today our functional mushroom nutraceutical product, GOODMIND™ is available online. The GOODMIND™ formulas harness the power of adaptogens, these are non-toxic, non-psychoactive fungi, used for centuries in traditional medicine for their stress-relieving benefits. GOODMIND™ is designed to nourish the mind and elevate everyday life by enhancing mental capacity and the body’s ability to adapt to stress.

  • Diary of a psychedelic exec | episode 06 | Psyence

The Diaries of a Psychedelic Exec : Episode 6

2021-07-22T11:50:31+00:00July 22, 2021|Investor Information, Diary Of A Psychedelic Exec|

Hi, I am Neil Maresky, the new CEO of Psyence. I am delighted to be able to make a contribution to the “Diary of a Psychedelic Exec”. In this episode I reflect on the challenges society is facing when it comes to mental health and why I think psychedelics, and Psyence in particular, have an important role to play in addressing these challenges. I feel privileged to have the opportunity to lead an incredible team at Psyence, all of whom are clearly committed to making an impact on society.

  • The Diaries of a Psychedelic Exec : Episode 4

The Diaries of a Psychedelic Exec : Episode 5

2021-07-12T08:35:32+00:00July 12, 2021|Investor Information, Diary Of A Psychedelic Exec|

It was another exciting week at Psyence as we welcomed Dr. Neil Maresky as Chief Executive Officer of Psyence Group. Based in Canada, Neil brings over twenty years of biopharmaceutical experience to Psyence; he was previously at AstraZeneca. I am now the Executive Chairman of Psyence Group and will work closely with Neil on all aspects of the business going forward. I am also delighted to share news of our partnership agreement with Clerkenwell Health; a leading psychedelic Contract Research Organisation based in the United Kingdom.

  • Clerkenwell | Psyence | Psilocybin

Psyence Group and UK Psychedelic CRO Partners to Conduct UK Palliative Care Clinical Trial

2021-07-07T11:41:13+00:00July 7, 2021|Press Releases, Investor Information, Psychedelic News|

Psyence has signed a partnership agreement with Clerkenwell Health, a leading psychedelic Contract Research Organisation (CRO) based in the United Kingdom to develop market leading clinical trials in the field of palliative care. Clerkenwell will be responsible for jointly designing and delivering the UK clinical trial. Palliative care is the treatment and alleviation of suffering for those facing a serious acute or persistent medical issue, whether the prognosis is deemed terminal or chronic and ongoing.

  • Neil Maresky

Psyence Group Announces Appointment of New Chief Executive Officer

2021-06-28T14:41:30+00:00June 28, 2021|Press Releases, Investor Information|

Today Dr. Neil Maresky joins Psyence as Chief Executive Officer. Dr. Maresky brings more than 20 years of biopharmaceutical expertise to our team; he will oversee strategy and operations of Psyence, and will be based in Canada. Dr. Maresky has been instrumental in the launch, commercialization, and uptake of many ground breaking innovations, which have positively impacted the health of millions of patients across Canada.

Go to Top